Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
J Gastrointest Cancer. 2010 Mar;41(1):17-23. doi: 10.1007/s12029-009-9092-9.

Stem cell therapy improves the outcome of liver resection in cirrhotics.

Author information

  • 1General Surgery, Liver Research Unit, Stem Cell Research Division, Faculty of Medicine, Ain Shams University, Cairo, Egypt. ahismail2002@yahoo.com

Abstract

INTRODUCTION:

Significant proportions of liver cirrhotic patients develop hepatocellular carcinoma and have to undergo hepatic resection. The compromised cirrhotic liver cannot withstand further removal of hepatic tissue, thus, leading to postoperative complication and death.

METHODS:

In this study, we enrolled 20 patients having liver cirrhosis with hepatocellular carcinoma and randomly assigned them into two groups to receive autologous stem cells or placebo.

RESULTS:

After 3 weeks, all participants underwent liver resection and were followed for 12 weeks postoperative. We observed that the group receiving preoperative stem cell therapy had shown a significant improvement in all parameters of liver function and had no postoperative complications compared to the group treated with placebo, which showed no improvement in liver parameters and had postoperative complications.

DISCUSSION:

In conclusion, autologous stem cell therapy can improve the surgical outcome in cirrhotic livers and should be considered as an adjuvant treatment in such patients undergoing hepatic resection.

PMID:
20012230
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk